6 Biotechnology Stocks to Buy Now

Popular Posts: 4 Pharmaceutical Stocks to Buy Now8 Oil and Gas Stocks to Buy Now5 Pharmaceutical Stocks to Buy Now Recent Posts: 6 Biotechnology Stocks to Buy Now 4 Commercial Services Stocks to Buy Now 33 Commercial Banking Stocks to Buy Now View All Posts

The grades of six biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

Inovio Pharmaceuticals, Inc. () is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Inovio Pharmaceuticals engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. In Portfolio Grader’s specific subcategory of Sales Growth, INO also gets an A. .

This week, KYTHERA Biopharmaceuticals, Inc. () pushes up from a C to a B rating. KYTHERA Biopharmaceuticals focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market. .

This week, Alkermes Plc () is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Alkermes is a fully integrated biotechnology company committed to developing medicines that will improve patients’ lives. Shares of ALKS have increased 15.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. .

Gilead Sciences, Inc. () gets a higher grade this week, advancing from a B last week to an A. Gilead is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. Wall Street has pushed the stock higher by 5.9% over the past month. .

PDL BioPharma, Inc. () shows solid improvement this week. The company’s rating rises from a C to a B. PDL BioPharma engages in intellectual property asset management and patent portfolio and related assets investment activities. Investors have pushed the stock price up 6.6% over the past month. .

Isis Pharmaceuticals, Inc. () is seeing ratings go up from a B last week to an A this week. Isis Pharmaceuticals discovers and develops novel human therapeutic compounds. Wall Street seems to agree with the upgrade and has propelled the stock up 17.2% over the past month. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.